GP-119
/ GliaPharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 20, 2023
GliaPharm receives USD 4.2 million to propel Alzheimer’s treatment development
- "Dr. Howard Fillit...has highlighted the significance of this development: 'Developing new drugs that regulate brain metabolism in ageing bodies, like GliaPharm's GP-119, is a promising approach for treating Alzheimer's and related dementias. We hope to develop an arsenal of drugs that can stop the disease in its tracks through combination therapy and precision medicine.'"
Media quote
1 to 1
Of
1
Go to page
1